Autumn 2023 Press Review – Lancet Rheum

April 2023 to July 2023

Authors: Olivier Fakih and Clementina López-Medina

The Lancet Rheumatology

Secukinumab efficacy and safety in Giant Cell Arteritis

Venhoff et al (doi:10.1016/S2665-9913(23)00101-7) conducted a phase 2 trial evaluating secukinumab (SEC) in patients with giant cell arteritis. The SEC group exhibited a 70% sustained remission rate at week 28 versus 20% in the placebo group. Adverse events were comparable between the two groups. The authors concluded that SEC is effective and well-tolerated for treating giant cell arteritis.

Colchicine in hand osteoarthritis pain management

Døssing A et al (doi:10.1016/S2665-9913(23)00065-6) investigated colchicine’s efficacy for hand osteoarthritis. No significant relief in finger pain was observed compared to placebo, and colchicine was associated with more adverse events. The study concluded that colchicine is not effective for pain relief in hand osteoarthritis.

Pregnancy outcomes in women with primary Sjögren’s Syndrome

Martin de Frémont G et al (doi:10.1016/S2665-9913(23)00099-1) evaluated pregnancy outcomes in women with primary Sjögren’s syndrome (pSS). The study found no increased risk of adverse pregnancy outcomes in women with pSS compared to the general population. They concluded that pregnancies in women with pSS have very good prognoses.

Comparative efficacy of treatments for multisystem inflammatory Syndrome in Children

Channon-Wells et al (doi:10.1016/S2665-9913(23)00029-2) assessed treatment options for children with multisystem inflammatory syndrome (MIS-C). No significant difference in primary outcomes (ventilation, inotropic support, or death) was observed between intravenous immunoglobulin alone and other treatment combinations. They concluded that initial treatment with glucocorticoids appears to be a safe alternative.

Olivier Fakih
Olivier is a rheumatology resident at the Department of Rheumatology of Besançon University Hospital in France. His research interests include the epidemiology of inflammatory rheumatic diseases, in particular mortality and comorbidities in spondyloarthritis. Olivier is a member of the French Society of Rheumatology and the society’s young rheumatologists section (REF). He is a member of the EMEUNET Social Media sub-committee, in the podcast team.

Clementina López-Medina
Clementina López-Medina is a Rheumatologist and postdoctoral researcher at the Spondyloarthritis Unit of the Reina Sofia University Hospital in Cordoba, Spain. Her work focuses on the epidemiology and clinical phenotypes of Spondyloarthritis. Clementina is a member of the Social Media Sub-Committee.

Leave a Reply